Skip to main content
Equibles
DAWN logo

DAWN · Day One Biopharmaceuticals, Inc.

Track DAWN — free Ask ALVIS about DAWN
$21.53 +0.00 (+0.00%) At close · Apr 24
Market Cap
$2.22B
Shares
103.33M

Day One Biopharmaceuticals, Inc. Earnings Call Transcripts

Every quarterly earnings call for Day One Biopharmaceuticals, Inc. (DAWN) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $8.19M −$4.41M '24 Q2 24-07-30 · $93.76M $37.04M '24 Q3 24-10-30 · $29.21M −$95.47B '24 Q4 25-01-13 · $30.76M −$36.00M '25 Q1 25-05-06 ▲313.9% $33.91M −$30.32M '25 Q2 25-08-05 ▼57.6% $39.80M −$19.73M '25 Q3 25-11-04 LATEST ▲83.9% $53.72M −$107.24B '25 Q4 26-02-24
Earnings call
FY25 · Q4
2026-02-24
Day One Biopharmaceuticals, Inc. Q4 FY2025 Earnings Call
Confident tone Ojemda (tovorafenib) commercial uptake in pLGG 2026 revenue guidance EMILY ADC program (Mersana) in ACC
Revenue
$53.72M*
▲ 83.9% YoY
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Day One Biopharmaceuticals, Inc. Q3 FY2025 Earnings Call
Confident tone OJEMDA Commercial Launch Momentum Physician Adoption and Payer Access Revenue Growth and Guidance Raise
Revenue
$39.80M
▼ 57.6% YoY
Diluted EPS
$-0.19
▼ 150% YoY
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Day One Biopharmaceuticals, Inc. Q2 FY2025 Earnings Call
Confident tone OJEMDA commercial performance Prescribing breadth and depth Rash management and persistence
Revenue
$33.91M
▲ 313.9% YoY
Diluted EPS
$-0.29
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Day One Biopharmaceuticals, Inc. Q1 FY2025 Earnings Call
Confident tone OJEMDA commercial performance and revenue growth European expansion via Ipsen partnership DAY301 Phase Ia dose escalation
Revenue
$30.76M
Diluted EPS
$-0.35
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Day One Biopharmaceuticals, Inc. Q4 FY2024 Earnings Call
Confident tone OJEMDA Commercial Launch DAY301 ADC Pipeline FIREFLY-2 Frontline Trial
Revenue
$29.21M*
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Day One Biopharmaceuticals, Inc. Q3 FY2024 Earnings Call
Confident tone OJEMDA Commercial Launch DAY301 PTK7 ADC Pipeline Ipsen Ex-U.S. Partnership
Revenue
$93.76M
Diluted EPS
$0.38
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-30
Day One Biopharmaceuticals, Inc. Q2 FY2024 Earnings Call
Revenue
$8.19M
Diluted EPS
$-0.05
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-26
Day One Biopharmaceuticals, Inc. Q4 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q1
2023-05-01
Day One Biopharmaceuticals, Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-0.59
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-06
Day One Biopharmaceuticals, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q2
2022-08-04
Day One Biopharmaceuticals, Inc. Q2 FY2022 Earnings Call
Diluted EPS
$-0.60
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-07
Day One Biopharmaceuticals, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–12 of 12 earnings calls
Key facts CIK 1845337 CUSIP 23954D109 13F (30d) 1 filings 1 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)